Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 January 2006, Vol. 107, No. 2, pp. 642-650.
Prepublished online as a Blood First Edition Paper on September 22, 2005; DOI 10.1182/blood-2005-07-3041.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-07-3041v1
107/2/642    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bilancio, A.
Right arrow Articles by Vanhaesebroeck, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bilancio, A.
Right arrow Articles by Vanhaesebroeck, B.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted July 28, 2005
Accepted September 8, 2005

Key role of the p110{delta} isoform of PI3K in B cell antigen and IL4 receptor signalling - comparative analysis of genetic and pharmacological interference with p110{delta} function in B cells

Antonio Bilancio, Klaus Okkenhaug, Montserrat Camps, Juliet L. Emery, Thomas Ruckle, Christian Rommel, and Bart Vanhaesebroeck*

Ludwig Institute for Cancer Research, London, United Kingdom
Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, United Kingdom
Serono, Serono Pharmaceutical Research Institute, Serono International S.A., Geneva, Switzerland
Ludwig Institute for Cancer Research, London, United Kingdom; Department of Biochemistry and Molecular Biology, University College London, London, United Kingdom

* Corresponding author; email: bartvanh{at}ludwig.cul.ac.uk.

Mouse gene targeting studies have documented a central role of the p110{delta} isoform of phosphoinositide 3-kinase (PI3K) in B cell development and function. A defect in B cell antigen receptor (BCR) signalling is key to this B cell phenotype. Here we further characterise this signalling defect and report that a p110{delta}-selective small molecule inhibitor mirrors the effect of genetic inactivation of p110{delta} in BCR signalling. p110{delta} activity is indispensable for BCR-induced DNA synthesis and phosphorylation of Akt/protein kinase B (PKB), forkhead transcription factor/forkhead box O3a (FOXO3a) and p70 S6 kinase (p70 S6K), with modest effects on the phosphorylation of glycogen synthase kinase 3{alpha}/{beta} (GSK3{alpha}/{beta}) and extracellular signal-regulated kinase (Erk). The PI3K-dependent component of intracellular calcium mobilisation also completely relies on p110{delta}-catalytic activity. Resting B cells with inactive p110{delta} fail to enter the cell cycle, correlating with an incapacity to upregulate the expression of cyclin D2, A and E and to phosphorylate the retinoblastoma protein (Rb). p110{delta} is also critical for interleukin 4 (IL4)-induced phosphorylation of Akt/PKB and FOXO3a, and protection from apoptosis. Taken together, these data show that defects observed in p110{delta} mutant mice are not merely a consequence of altered B cell differentiation, and emphasise the potential utility of p110{delta} as a drug target in auto-immune diseases in which B cells play a crucial role.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Knock-outs and inhibitors: one and the same?
Zachary A. Knight and Kevan M. Shokat
Blood 2006 107: 420-421. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Sauer, L. Bruno, A. Hertweck, D. Finlay, M. Leleu, M. Spivakov, Z. A. Knight, B. S. Cobb, D. Cantrell, E. O'Connor, et al.
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
PNAS, June 3, 2008; 105(22): 7797 - 7802.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
T. Doi, K. Obayashi, T. Kadowaki, H. Fujii, and S. Koyasu
PI3K is a negative regulator of IgE production
Int. Immunol., April 1, 2008; 20(4): 499 - 508.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Ali, M. Camps, W. P. Pearce, H. Ji, T. Ruckle, N. Kuehn, C. Pasquali, C. Chabert, C. Rommel, and B. Vanhaesebroeck
Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110{delta} but Not p110{gamma} Promotes Optimal Allergic Responses In Vivo
J. Immunol., February 15, 2008; 180(4): 2538 - 2544.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. L. Janas, D. Hodson, Z. Stamataki, S. Hill, K. Welch, L. Gambardella, L. C. Trotman, P. P. Pandolfi, E. Vigorito, and M. Turner
The Effect of Deleting p110{delta} on the Phenotype and Function of PTEN-Deficient B Cells
J. Immunol., January 15, 2008; 180(2): 739 - 746.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Ji, F. Rintelen, C. Waltzinger, D. Bertschy Meier, A. Bilancio, W. Pearce, E. Hirsch, M. P. Wymann, T. Ruckle, M. Camps, et al.
Inactivation of PI3K{gamma} and PI3K{delta} distorts T-cell development and causes multiple organ inflammation
Blood, October 15, 2007; 110(8): 2940 - 2947.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
P. R. Cutillas and B. Vanhaesebroeck
Quantitative Profile of Five Murine Core Proteomes Using Label-free Functional Proteomics
Mol. Cell. Proteomics, September 1, 2007; 6(9): 1560 - 1573.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Geering, P. R. Cutillas, G. Nock, S. I. Gharbi, and B. Vanhaesebroeck
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers
PNAS, May 8, 2007; 104(19): 7809 - 7814.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
C. Riou, B. Yassine-Diab, J. Van grevenynghe, R. Somogyi, L. D. Greller, D. Gagnon, S. Gimmig, P. Wilkinson, Y. Shi, M. J. Cameron, et al.
Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells
J. Exp. Med., January 22, 2007; 204(1): 79 - 91.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020